141 related articles for article (PubMed ID: 1761351)
1. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase.
Peake PW; Pussell BA; Martyn P; Timmermans V; Charlesworth JA
Int J Immunopharmacol; 1991; 13(7):853-7. PubMed ID: 1761351
[TBL] [Abstract][Full Text] [Related]
2. Rosmarinic acid: a new inhibitor of complement C3-convertase with anti-inflammatory activity.
Englberger W; Hadding U; Etschenberg E; Graf E; Leyck S; Winkelmann J; Parnham MJ
Int J Immunopharmacol; 1988; 10(6):729-37. PubMed ID: 3198307
[TBL] [Abstract][Full Text] [Related]
3. Anti-complement activity of oleanolic acid: an inhibitor of C3-convertase of the classical complement pathway.
Kapil A; Sharma S
J Pharm Pharmacol; 1994 Nov; 46(11):922-3. PubMed ID: 7897600
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).
Feuillard J; Maillet F; Goldschmidt P; Weiss L; Kazatchkine MD
Agents Actions; 1991 Mar; 32(3-4):343-6. PubMed ID: 1862751
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b.
Sahu A; Rawal N; Pangburn MK
Biochem Pharmacol; 1999 Jun; 57(12):1439-46. PubMed ID: 10353266
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effect of factor J on the alternative complement pathway.
González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
[TBL] [Abstract][Full Text] [Related]
7. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
8. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
Sobel AT; Cooper NR; Schreiber RD
J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
[TBL] [Abstract][Full Text] [Related]
9. Distal recognition site for classical pathway convertase located in the C345C/netrin module of complement component C5.
Sandoval A; Ai R; Ostresh JM; Ogata RT
J Immunol; 2000 Jul; 165(2):1066-73. PubMed ID: 10878385
[TBL] [Abstract][Full Text] [Related]
10. Regulation of C5 convertase activity by properdin, factors B and H.
Weiler JM
Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
[No Abstract] [Full Text] [Related]
11. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
13. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
Weiler JM; Gleich GJ
J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
[TBL] [Abstract][Full Text] [Related]
14. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the alternative pathway of complement by glomerular chondroitin sulphate proteoglycan.
Quigg RJ
Immunology; 1992 Jul; 76(3):373-7. PubMed ID: 1382039
[TBL] [Abstract][Full Text] [Related]
16. Anticomplementary activity of boswellic acids--an inhibitor of C3-convertase of the classical complement pathway.
Kapil A; Moza N
Int J Immunopharmacol; 1992 Oct; 14(7):1139-43. PubMed ID: 1452399
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition of the classical pathway of human complement by a natural microbial product, colistin sulphate.
Asghar SS; de Koster A; van der Helm HJ
Biochem Pharmacol; 1986 Sep; 35(17):2917-21. PubMed ID: 3638137
[TBL] [Abstract][Full Text] [Related]
18. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
Kozlov LV; Soliakov LS; Zinchenko AA
Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
[TBL] [Abstract][Full Text] [Related]
19. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity.
Ebanks RO; Isenman DE
Mol Immunol; 1996 Feb; 33(3):297-309. PubMed ID: 8649451
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
Strunk RC; Webster RO
Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
